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POPULAR SCIENCE SUMMARY OF THE THESIS 
 
In an aging society such as Sweden, legislators will face more and more challenges regarding 
treatment of individuals with dementia. Caring for persons suffering from dementia poses various 
ethical challenges about how to find balance between their autonomy, well-being, and safety. 
Additionally, the caregiver will sometimes have to face difficult decisions regarding the proper 
therapy for non-cognitive symptoms that almost all individuals with dementia experience during 
the course of their illness. 
This Thesis covers the subject of Behavioral and psychological symptoms of dementia (BPSD). 
BPSD refers to all non-cognitive symptoms of dementia, such as psychotic and affective 
symptoms, hyperactivity, and apathy. The first study describes BPSD in various dementia 
diagnoses, whereas the second study focuses on the link between unmet needs and BPSD. The 
first two studies included only individuals residing in long-term care facilities. In Study 3, the 
risk of death associated with antipsychotic treatment was investigated. Study 4, on the other hand, 
concerns an issue that has not received much attention, especially among European researchers. 
More specifically, we used the Swedish Register for Cognitive Disorders / Dementia (SveDem) 
to describe firearm ownership in individuals with dementia in Sweden and investigate which of 
the registered characteristics of the person were considered by doctors when they reported the 
person as unfit to have a firearm. 
In summary, we found that BPSD is common in individuals with dementia residing in long-term 
care facilities, in particular aberrant motor behavior, agitation/aggression and irritability. 
Additionally, we observed that individuals with dementia may have several of their needs unmet, 
the most common of which were pain, sleeping problems, impaired hearing and vision. 
Importantly, there was a relationship between the number of unmet needs and BPSD in each type 
of dementia. We also found that individuals with dementia are administered both typical and 
atypical antipsychotics. Their use was associated with a higher risk of death. In our cohort, 3.4% 
of individuals owned a firearm. Owners of firearms were typically younger males who were still 
living more independent lives. The decision to remove the firearm was not decided just on the 
premise of a dementia diagnosis, but rather on the basis of a number of factors, such as type of 







Most people with dementia suffer behavioral and psychological symptoms (BPSD). These 
symptoms add to caregiver stress and accelerate cognitive decline. The etiology of BPSD is 
complex, with multiple factors influencing symptom manifestation. The ability to 
accommodate and communicate needs decreases with cognitive deterioration. Unmet needs 
may explain why some individuals, despite having the same diagnosis and degree of cognitive 
impairment, have more severe BPSD. BPSD is treated with both atypical and typical 
antipsychotics (APD). Numerous studies demonstrated that APD treatment in individuals with 
dementia might cause major side effects, including death. The purpose of this Thesis is to 
examine factors associated with BPSD in a large group of individuals with dementia. 
The Thesis covers four cross-sectional investigations using data from five Swedish registries: 
The Swedish registry for cognitive/dementia disorders (SveDem), the Swedish Behavioral and 
psychological symptoms of dementia Registry (BPSD registry), the Swedish Prescribed Drug 
Registry (SPDR), the Swedish Cause of Death Registry (CODR), and the Swedish National 
Patient Registry (NPR). Six types of diagnoses were included in the studies: Alzheimer’s 
disease (AD), vascular dementia (VaD), mixed (Mixed) dementia, Parkinson’s disease 
dementia (PDD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD) and 
unspecified dementia (UNS). 
In Study 1, we discovered that 75% of individuals with dementia exhibited at least one 
clinically significant BPSD, the most prevalent being aberrant motor behavior, 
agitation/aggression and irritability. In comparison to AD, we found a lower risk of delusions 
(in FTD, UNS), hallucinations (FTD), agitation (VaD, PDD, UNS), elation/euphoria (DLB), 
anxiety (Mixed, VaD, unspecified dementia), disinhibition (in PDD); irritability (in DLB, FTD, 
UNS), aberrant motor behavior (Mixed, VaD, UNS), sleep and night-time behavior changes 
(UNS). Higher risk of delusions (DLB), hallucinations (DLB, PDD), apathy (VaD, FTD), 
disinhibition (FTD) and appetite and eating abnormalities (FTD) were also found in 
comparison to AD. In Study 2, pain was the most prevalent unmet need, followed by sleeping 
disturbances, impaired hearing and impaired vision. Additionally, we found that the risk of 
BPSD increases with unmet physical or psychological needs in dementia. In Study 3, APD use 
at the time of dementia diagnosis was associated with increased mortality risk across the cohort 
and by dementia subtype. In Study 4, we found that out of 53,384 individuals with dementia, 
1,823 owned a firearm and 419 were unfit owners. Owners of firearms were mostly male, 
younger, living alone and without homecare support. Living with another person, 
frontotemporal dementia, APD and hypnotics prescription, being diagnosed in a 
memory/cognitive clinic, female gender, and mild and moderate dementia were the most 
important predictors of being reported to the police. 
 
In conclusion, individuals with dementia who live in long-term care facilities frequently 
develop BPSD. Additionally, unmet needs are significantly associated with BPSD in each 
dementia type. Individuals with dementia receive both typical and atypical APDs, however, 
their use is associated with an increased risk of death. Finally, we found that the decision to 
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Dementia is a syndrome that can be caused by several etiologies with the Alzheimer’s Disease 
(AD) being the most common form of dementia. Cognitive impairment is considered the 
hallmark of dementia, however, in addition to it all individuals with dementia will experience 
at least one behavioral and psychological symptom of dementia (BPSD) in the course of the 
disease.1   
Although BPSD has been somewhat neglected in dementia research, it was identified as an 
integral component of dementia disorders even in the earliest accounts of dementia. In his 
classic early-twentieth-century case report of the disease, Alois Alzheimer recognized 
behavioral abnormalities as prominent manifestations in his case description.2 Paranoia,  sleep 
disorders, aggressiveness, crying, and progressive confusion accompanied disturbances of 
memory of the first AD patient.3 However, only in the 1980s did BPSD become an important 
subject of clinical and scientific discussion. Finally, it was in 1999 when the term BPSD was 
introduced by the International Psychiatric Association (IPA) replacing the former term 
“behavioral disturbances“.4 IPA adopted the general definition of BPSD operationalizing  them 
as “symptoms of disturbed perception, thought content, mood, or behavior that frequently occur 
in patients with dementia.”5  BPSD are widespread in all subtypes of dementia but typically 
differ in the frequency and severity of individual symptoms in individuals with different 
diagnoses of dementia.6 Although many studies have reported the presence of these symptoms 
in dementia, they reported inconclusive findings. Additionally, their conclusive description is 
complicated by the complex etiology of BPSD and the tendency of some of BPSD to fluctuate 
in time, while other remaining relatively stable.7,8 
Nowadays, BPSD are studied and commonly found with similar prevalence across different 
continents around the world in countries such as Australia,9 Central African Republic and 
Republic of Congo,10 Chile,11 China,12 Hungary,13 Norway,14 Taiwan,15 Tanzania,16 the 
Netherlands,17 the United States,18 among others. The widespread presence and high 
prevalence of BPSD is a matter of concern. These symptoms have been identified as a major 
contributor to the burden of both patients and their caregivers, moving to long-term care 
facilities, higher morbidity and greater rates of mortality.6 Care for relatives with BPSD is 
associated with reduced quality of life, poorer health and lower income from work.19,20 Finally, 
BPSD also play an important role in ethical dilemmas related to management of behavior of 
individuals with dementia. In order to ensure safety of individuals with dementia and their 
 
2 
environments, caregivers will have to assess the potential risk that the behavior can cause and 
implement appropriate prevention and treatment. For these reasons, in the past few years, there 
has been an increasing worldwide effort to place BPSD in a more central position in the 




2 LITERATURE REVIEW 
 
2.1 ASSESSMENT OF BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF 
DEMENTIA 
 
A number of tools to assess BPSD has been growing with eighty‐three instruments identified 
by 2014.21 Currently, the Neuropsychiatric Inventory (NPI) is the most common tool to assess 
BPSD.22 It was developed in 1994 by Cummings et al.23 Even though it was originally meant 
to target individuals with dementia, it is currently also used to examine individuals with 
psychotic, affective, and other neurological illnesses, including Parkinson's disease and 
epilepsy. The NPI has been translated into a variety of languages, such as Chinese, Danish, 
Dutch, French, German, Greek, Hebrew, Italian, Japanese, Norwegian, Portuguese, Spanish, 
Swedish, and Thai.  
Prior to the NPI, neuropsychiatric research in dementia mostly relied on techniques designed 
for mental diseases including schizophrenia and major depressive disorder.24 However, 
symptoms observed in dementia differed from a presentation of psychiatric disorders, 
necessitating the development of a tool specific for this group of individuals. For example, the 
Hamilton Depression Rating Scale (HDRS), which is used to evaluate mood changes in major 
depressive disorder, includes features of depression such as withdrawal, appetite changes, and 
sleep disturbances that may occur in dementia without depression. In contrast, the 
depression/dysphoria domain of the NPI only covers mood-related items, while apathy, sleep 
changes, and appetite changes are separate items of NPI. 
When it was initially created, NPI evaluated ten behavioral disorders: delusions, hallucinations, 
dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, 
and aberrant motor behavior. The measure was then modified and expanded to 12 categories, 
including night-time behavior disturbances as well as appetite and eating abnormalities.  The 
NPI is a quantitative measure in a form of a semi-structured interview with a caregiver. 
According to Cummings et al., caregivers are the most optimal informants of the behavior of 
the person with dementia, since this group of individuals is deemed unable to recall or explain 




The NPI evaluates not only the presence of each behavior, but also its frequency and severity. 
The frequency of symptoms is scored on a four-point scale from 1 to 4 (1: occasionally, 2: less 
than once a week, 3: very frequently, 4: more than once a day) and the severity of the behavior 
is rated on a three-point scale (1: mild, 2: moderate, or 3: severe). Additionally, caregivers are 
asked to assess the distress associated with caring for an individual with a given symptom on a 
6-point scale (0: not at all distressing, 1: minimally distressing, 2: mildly distressing, 3: 
moderately  distressing, 4:severely distressing  and 5: very severely or extremely  distressing). 
Despite being a frequently used and valuable tool, NPI is not without limitations.25 First of all, 
Cummings et al., did not provide a conceptual framework behind the NPI.23 Symptoms were 
chosen based on the extensive literature review and then categorized into domains. Although 
it is not stated explicitly, NPI seems to reflect the biomedical perspective in the approach to 
diseases, that is the disease causes symptoms, hence an assessment of the symptoms' response 
to therapy is required. This also implies that NPI does not place so much importance on the 
significance of the symptoms but only quantifies them. This offers both advantages and 
disadvantages. There is no attempt to identify if behaviors are caused by the physical or social 
environment, other unmet needs or medical reasons. For this reason, it does not encourage 
reflection about the underlying reasons of the behavior and may result in detection biases when 
behaviors are indiscriminately attributed to BPSD. However, the instrument is easy and quick 
to administer which is important in clinical settings. 
Second, the NPI does not seek to understand the perspective of the individuals with dementia 
themselves in assessing their symptom. Failing to include the perspective of persons whose 
behavior is a matter of observations risks not only clinical problems but is also ethically 
concerning. For example, McKinlay et al. compared caregiver and self-reports about BPSD 
using the NPI.26 Although both patients and caregivers reported similar rates of symptoms, the 
researchers found that there was little agreement amongst the dyads. The authors speculated 
that the lack of agreement may be due to caregivers being asked to report on issues that were 
not immediately apparent based on observed behavior and concluded that caregiver and patient 
reports cannot be considered interchangeable. Additionally, another study indicated that it is 






2.2 ETIOLOGY OF BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF 
DEMENTIA (BPSD) 
 
2.2.1 Models of Behavioral and psychological symptoms of dementia 
(BPSD) 
An integral challenge in developing a unifying framework for BPSD is its heterogeneous 
presentation and etiology. Although BPSD primarily results from pathophysiological changes 
in the brain, neurodegeneration only explains part of its manifestation. BPSD is a complex 
phenomenon involving also other factors, such as comorbidity, characteristic of the 
environment and individual personality traits. Currently, there are few prevailing theoretical 
frameworks of BPSD – the unmet needs models, the need-driven, dementia-compromised 
behavior model, the behavioural/learning model and the environmental vulnerability/reduced 
stress-threshold models.28 
Unmet needs model 
Unmet needs model focuses on the relationship between unmet needs and the relationship with 
BPSD. Unmet needs are defined as the needs that are not readily evident to the observer or 
caregiver, or that caregivers do not feel they are capable of meeting.29 According to the unmet 
needs model cognitive decline impairs the one's ability to meet one's requirements as 
communication becomes more difficult, as well as the one's ability to provide for oneself.29,30 
In this perspective, BPSD result from a combination of  lifelong habits, personality, current 
physical and mental states with not optimal environmental conditions. For example, in this 
model agitation could have a compensatory function (alleviation of boredom) as well as 
communicatory - to communicate the need to a caregiver. 
The need-driven, dementia-compromised behavior model 
According to the need-driven, dementia-compromised behavior model,31,32 BPSD is caused by 
the caregiver's failure to comprehend needs and the incapacity of the individual with dementia 
to communicate those needs. Therefore, in this view, BPSD is a symptom of unmet needs. 
Furthermore, the model distinguishes between background factors and proximal factors that 
interacts to cause BPSD. Neurological, health, and psychosocial factors constitute relatively 
stable, background factors. On the other hand, proximal factors - current situational issues and 
events - are more susceptible to change and often directly antedate the BPSD. Proximal factors 
include variables within the person (e.g. pain, fatigue), physical environment (e.g. noise, room 
temperature), and social environment.  
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The behavioural/learning model  
The ‘behavioural/learning’ model proposes that BPSD is formed through caregiver 
reinforcement (e.g. caregiver’s attention) in the conditioning process.28 This means, that a 
connection between antecedents, behavior, and reinforcement has been learned, and to change 
this connection, a different learning experience is needed. Antecedents-Behaviour-
Consequences (A-B-C) approach to management of BPSD entails tracing antecedent factors to 
the expression of BPSD, and reviewing the consequences, which may unintentionally reward 
the person and thereby reinforce BPSD. 
Environmental vulnerability/reduced stress-threshold model 
Environmental model associates the occurrence of BPSD with the mismatch between the needs 
and abilities of the individuals with dementia and their environment. Progressive lower stress 
threshold model posits that individuals with dementia have a lowered stress threshold and 
thereby progressively lose their coping abilities. This leads them to perceive their environment 
as more and more stressful.33 Environmental conditions optimal for a cognitively healthy 
person can therefore exceed ability of the individual with dementia to cope and adapt. Thus, 
intervention strategies based on this model focus on creating a less stressful environment by 
considering the individuality of the individual with dementia, focusing on their interaction with 
the environment, and adapting the environment to the reduced cognitive capacities of the 
individuals with dementia. 
2.2.2 Kales and colleagues comprehensive model of BPSD 
The various models of BPSD are not mutually exclusive. Due to the lower stress threshold, 
individual with dementia can be more susceptible to environmental antecedents and 
consequences. Additionally, the lower stress threshold may lead to unmet needs when normal 
levels of stimulation are interpreted as overstimulation. Further, individual symptoms may 
differ in their etiologies and the trajectories leading to symptoms vary between individuals with 
dementia. Kales and colleagues34 proposed a comprehensive model explaining how different 
dementia-related factors increase the vulnerability to stressors and thereby disrupt the ability 
of patients to functionally interact with others, contributing to the occurrence of BPSD. These 
factors were categorized into those associated with: a) the patient (brain pathology, unmet 
needs, comorbidity and medication, premorbid personality), b) the environment (e.g. 
stimulation), and c) the caregiver (e.g. stress, coping strategies, perceived burden). Dementia, 
according to their model, may directly induce symptoms by altering brain circuitry involved in 
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behavior and emotion. Additionally, behaviors can be triggered by caregiver and environmental 
factors alone or in combination with the circuit abnormalities seen in brain degeneration.  
Patient-related factors 
Neurobiology. Neurobiological factors, according to the need-driven, dementia-compromised 
behavior model, are distant factors that interact with the environment resulting in BPSD. 
However, BPSD most likely cannot be linked to single-brain atrophy, dysfunctions or 
neurochemical alterations in the brain. Similar to other psychiatric disorders, symptoms may 
be associated with multiple and distributed foci of structural brain abnormalities. Additionally, 
the same set of networks may be impacted across many different symptoms in different 
subtypes of dementia. Several parallel brain and behavioral mechanisms have been identified 
to underlie single BPSD or spectrum of symptoms. Frontal-subcortical circuits responsible for 
planning, executive function, motivation, inhibitory control and conformity with social norms 
are subject to neurodegeneration in dementia and correlate with BPSD.35,36 Additionally, 
imbalance of different neurotransmitters can contribute to the pathogenesis of behavioral 
abnormalities in dementia.37 For instance, monoaminergic neurotransmitters diffusely project 
to almost all regions of the brain involved in the regulation of behavior.37 Serotonin and 
dopamine have also been implicated in several BPSD.38,39 The cholinergic system represents 
the most important neuromodulatory neurotransmitter system in the brain and cholinergic 
deficits have been shown to contribute to several of BPSD.40  
Comorbidities. Individuals with dementia often may suffer from other medical problems or 
undetected diseases, with 66% of them having at least one undiagnosed disease.41 For example, 
bacteriuria, hyperglycemia, and anemia have been found common in individuals with 
dementia.42 Individuals with dementia are more likely than those without cognitive impairment 
to suffer from untreated medical conditions.42,43 They may not be able to appropriately 
communicate their symptoms, especially at the moderate to severe disease stage, making the 
identification of medical concerns a significant treatment difficulty.44,45 Treatment is further 
complicated by the unusual or asymptomatic presentation of diseases in elderly individuals, for 
example, the absence of pain in the presence of a disease that is known to produce pain, or lack 
of fever in the presence of a condition that is known to induce fever.46 Pre-existing dementia 
can be an additional factor associated with atypical presentations of illnesses.46 These 
conditions might lead to severe behavioral symptomatology if left untreated. From the 
perspective of the unmet need model of BPSD, individuals communicate their needs through 
behavior. Since the possibility of verbal report is limited, individuals may use their behavior as 
a channel of communication. Undetected diseases were shown to result in BPSD, including 
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agitation, repetitive questions, screams, delusions, hallucinations, depression42 or aberrant 
eating behavior.42,47 For example, pain and delirium can underlie sleeping abnormalities,48 
aggressive behavior,49,50 eating problems, wandering, irritability, distress51 and verbal/vocal 
behaviors.30,51 In addition, drugs and their side effects can cause BPSD symptoms.52–55 
Antipsychotics can lead to confusion or somnolence, increased appetite, sedation and 
fatigue.56,57 Selective serotonin reuptake inhibitors (SSRIs), a typical first-line therapy for 
depression, have been shown to induce apathy in older adults.58 Caregivers may mistake 
behaviors as indicating the need for more psychotropic medication rather than determining 
whether there is an undiagnosed medical condition or other unmet need. As a result, many 
individuals with dementia may receive inadequate or even harmful treatment, for example 
restraining or psychotropic medication.  
Personality. Despite the fact that numerous theories of personality have been developed, trait 
theory, has been the most widely used in studies exploring a link between personality and 
BPSD. Further, most of these studies involves a model that defines personality referring to Five 
Factor-theory (FFT). In FFT, traits are considered as basic tendencies that in combination with 
external influences can cause habitual patterns of behavior, thinking, and emotion.59 Traits can 
be inferred from behaviors that cluster around five dimensions: openness, conscientiousness, 
extraversion, agreeability and neuroticism. According to this viewpoint, traits are relatively 
stable over time, differ between individuals (for example, some people are outgoing while 
others are not), are largely consistent across settings, and influence behavior.60  
These dimensions are derived from a lexical method, which analyzes the natural-language 
terms people use to describe themselves and others.61 According to the lexical hypothesis, most 
socially relevant and conspicuous psychological traits have become embedded in natural 
language. Therefore, the personality vocabulary of natural languages provides a wide, but 
finite, set of characteristics that individuals speaking that language have found essential and 
useful in their daily interactions.  
Initially, researchers suggested that personality traits in persons over the age of 30 remained 
stable.62 Recent research, however, has found a peak in trait consistency at the age of 50, as 
well as intraindividual shifts in personality trait trajectories.63–65 Roberts et al. found that 
personality traits are malleable in old age.66 More specifically, their meta-analysis revealed 
decreases in openness and extraversion and increases in agreeableness and conscientiousness.66  
These findings were partially corroborated by a longitudinal study that showed declines in 
neuroticism and extraversion but stability in openness, agreeableness, and conscientiousness.67 
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Long-term prospective studies suggested that in preclinical AD, there are no personality 
changes that are an early sign of the disease.68  On the other hand, there are significant changes 
in personality with the beginning and progression of dementia, which are routinely observed 
by caregivers in retrospective study.68 Differences in personality traits in mild cognitive 
impairment (MCI) and AD in comparison to the premorbid state or healthy aging include 
increased neuroticism as well as decreased extraversion, openness, conscientiousness, and 
agreeableness.69,70   
Literature suggests that that of the five traits, neuroticism has the most associations with 
BPSD.71–74 Associations have been found between neuroticism and mood and aggression-
related symptoms, delusion, getting lost in familiar places, wandering off, being unable to be 
left alone, hallucinations, depression, periodic confusion, and an uncontrolled temper.71–74 
Regarding other traits, low premorbid agreeableness was associated with high levels of verbally 
aggressive behavior and high conscientiousness with less total BPSD, lower risk of getting lost 
in familiar places and higher independence and lower verbally nonaggressive behaviors.73,74 
Studies investigating the association between personality and BPSD in different subtypes of 
dementia are scarce. In AD, premorbid neuroticism was shown to be positively associated with 
depression75–77 and anxiety,78,79 and premorbid agreeableness was negatively related to 
agitation and irritability.79 One study investigating premorbid personality traits in DLB found 
negative associations between openness and anxiety, agreeableness and delusion, as well as 
conscientiousness and agitation.75 
The mechanisms underpinning the role of personality in developing individual BPSD are 
speculative. Personality shapes an individual’s reactions to stress, health behaviors, and 
engagement in physical, cognitive, and social activities over the lifetime.68 It is therefore 
possible that some of the behaviors and premorbid ways of being remain encoded in the ways 
the individual interacts with the surrounding environment after developing dementia.80 
Additionally, there may be some overlap in the brain structures and connectivity involved in 
personality traits and BPSD. For example, neuroticism was linked in previous studies to an 
altered connectivity between prefrontal cortex and amygdala.81,82 These abnormalities may 
underly emotional reactivity common in individuals with high scores in neuroticism.83 It has 
been suggested that neurodegenerative processes in dementia may enhance pre-existing 






Physical environment design is becoming more widely acknowledged as a valuable tool in the 
treatment of individuals with AD and other dementias, particularly that many elements of the 
environment, such as noise levels, room lighting, appropriate crowding, and homelike design, 
are quite simple to modify. Competence and Environmental Press Model, also referred to as 
the Person–Environment Fit model illustrates people's interactions with their surroundings and 
stresses the impact of person–environment fit on person’s emotions and behaviors.85 Match 
between environmental demand and the individual's capability, results in positive emotions and 
adaptive behaviors. However, demands that surpass or fall below an individual's competency 
level may lead to maladaptive behaviors and negative emotions.  
Due to the lower stress threshold in individuals with dementia, the correspondence between the 
individual’s competence and the demands of the environment is particularly important in this 
population.33 Physical environment can have a therapeutic effect on individuals with dementia, 
promoting well being and independence while also improving behavior and functionality.86,87 
On the other hand, malignant environment has been associated with dysregulation of behavior. 
For example, the number of staff in a unit in which an individual with dementia resides and its 
size can contribute to the occurrence of BPSD with , where facilities with more staff per patient 
are associated with less apathy.88 Big unit size or nursing home size is related to BPSD, while 
small unit size for and homelike environment improved social abilities, functionality, and well-
being.9,87,89 Moreover, low social density is positively connected with residents' behavior and 
social abilities.87 Another study indicated residents who had access to privacy were less anxious 
and aggressive.90 Moreover, access to different types of common spaces with varying ambiance 
was associated with less social withdrawn and depression.90 Further, bright light treatment has 
been shown to improve sleep, behavior and overall well-being.87 There is considerable 
evidence linking excessive noise levels to undesirable behavior, whereas pleasant noises have 
been proven to be favorably stimulating.91  
 Caregiver factors and social interactions 
The importance of positive social relationships in reaching psychological well-being cannot be 
overstated. Yet, it has been shown that the residents of long-term care facilities have little social 
contacts and spend significant amounts of time alone. It has been estimated that those with 
dementia spend up to 40% of their days doing nothing.92 However, similar to the general 
population, the interactions the person with dementia have with the others as well the 
characteristics of caregivers have an impact on their quality life. 
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Caring for individuals with dementia is associated with an enormous burden with over 40% of 
family caregivers experiencing clinically significant depression or anxiety.93–95 The burden of 
caring may be higher for older family caregivers, women, and if the person with dementia has 
more BPSDs.94,95 The strongest correlations between the caregiver’s burden and individual 
symptoms were found for delusions, followed by agitation/aggression, anxiety, 
irritability/lability, and dysphoria/depression.96 Additionally, the way the caregivers deal with 
the burden of caring and their strategies for dealing with stress may further contribute to the 
development of BPSD. For example, a higher caregiver’s burden and/or a lower quality of 
relationship contributes to the aggressive behavior.50 The quality of the interaction also matters 
with activities that undermine a resident’s preferences, goals, or status leading to more 
disrupted response from individuals with dementia. BPSD are also more likely to be observed 
when interactions are focused on task-centered care rather than person-centered care.97 Persons 
with dementia react positively to interaction concerning their own preferences. If the 
conversation is more generic, the resident's attitude is negative, and associated with negative 
verbalizations.92  
In line with this, studies found improved BPSD in individuals with dementia after caregiver-
oriented interventions.98,99 For example, after 12 months of care management, patients in the 
intervention group showed significant improvements in BPSD, and there was a significant 
reduction in caregiver stress compared to the control group. Furthermore, compared to the 
usual care group, there was no increase in the use of antipsychotics or sedative-hypnotic 
medicines in the intervention group.98 Another intervention, consisting of three components - 
caregiver education, stress management and coping skills training - resulted in reductions in 
distress and depression and BPSD.99 This is supported by recent meta-analyses summarizing 
caregiver oriented interventions, generally suggesting improvement of quality of life for 








2.3 BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN DIFFERENT 
DEMENTIA DIAGNOSES 
 
2.3.1 Alzheimer disease (AD) 
AD is the most common type of dementia and is associated with a progressive neuronal loss 
and cognitive impairment.102 The main pathological features of AD are the accumulation of 
amyloid β (Aβ) into plaques and hyperphosphorylation of tau into neurofibrillary tangles 
(NFT).102,103 The most frequent BPSD-symptoms observed in AD are apathy, followed by 
depression, aggression, anxiety and sleep disorder, while the least common was euphoria.104 
However, presentation of BPSD in AD may differ with respect to disease duration, age, study 
setting, education level and cognitive impairment.104 A recent longitudinal study showed that 
occurrence of BPSD in AD can be grouped into three discernible phases with irritability, 
depression and sleep disturbances occurring in early phases, followed by apathy, anxiety, 
agitation, and appetite changes and finally delusions, hallucinations, and aberrant motor 
behavior.105  
2.3.2 Vascular dementia (VaD) 
VaD is a heterogeneous disease associated with ischaemic, hypoperfusive, or haemorrhagic 
brain lesions.106 VaD can result from large-vessel disease, often associated with extensive 
cortical-subcortical damage, or due to small-artery disease and hypoperfusion, resulting in 
subcortical vascular disease.106,107 Cerebrovascular lesions disrupt prefrontal-subcortical loops 
(e.g. nuclei of the basal ganglia and thalamus) and thereby underpin executive function 
impairment108–110 and behavioral changes.111–113 Although apathy seems to be the most 
common symptom in VaD,114–116 individuals with VAD rank high also on depression, sleep 
disturbance,117 irritability and agitation.115 Moreover, the type of underlying vascular disease 
may be associated with different clinical profiles in VAD. Apathy, aberrant motor behavior, 
and hallucinations were shown to be more common in individuals with small-vessel VAD, 
whereas agitation and euphoria were more severe in those with large-vessel VAD.115  
2.3.3 Dementia with Lewy Bodies (DLB) 
The hallmark feature of DLB is the presence of numerous Lewy bodies composed of alpha-
synuclein in the brainstem, subcortical nuclei, limbic cortex (cingulate, entorhinal, amygdala), 
and neocortex (temporal, frontal, parietal).118  DLB is clinically characterized by the presence 
of dementia with deficits in attention, executive functions, visuo-spatial abilities but also 
memory impairment. The distinguishing features for the diagnosis of probable DLB are the 
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presence of fluctuating cognition, recurrent visual hallucinations and spontaneous motor 
features of Parkinsonism.118 Psychotic symptoms are therefore the most prevalent symptoms 
in DLB, with delusions occurring in up to 80% of patients and hallucinations in up to 60% of 
DLB patients.119 However, in addition to psychotic symptoms, a high prevalence of anxiety, 
depression, apathy, agitation, and sleep disorders have also been found.120,121   
2.3.4 Frontotemporal dementia (FTD) 
Clinical syndromes associated with frontotemporal lobar degeneration (FTLD) are 
characterized by progressive disintegration of the frontotemporal circuits and non-Alzheimer’s 
disease type pathology.122 The term FTD was introduced by the Lund&Manchester task force 
and refers specifically to the progressive behavioural syndrome.123 Although other FTLD 
syndromes - semantic dementia (characterized by anomia and progressive loss of knowledge 
about words and objects) and progressive nonfluent aphasia (characterized by hesitant, 
nonfluent speech) - differ in their clinical characteristics in the early stages, they eventually 
develop symptoms characteristic for FTD.124 Abnormal behavior is the core diagnostic feature 
of FTD.123 Common symptoms in this group of patients include stereotypic behavior,125–127 
loss of personal and social awareness,125,126 flattening of emotions, changes in appetite behavior 
(gluttony, food fads, sweet food preference), pacing, impaired insight, lack of pain awareness 
(however not so common), and hypersensitivity to neutral stimuli.128,129 
 
2.4 MANAGEMENT OF BEHAVIORAL SYMPTOMS OF DEMENTIA 
Caring for individuals with dementia raises ethical dilemmas of how to balance their autonomy 
and well-being, with their safety. With the increasing prevalence of dementia, public health 
workers will be challenged with new problems and some of them are particularly difficult 
because of their ethical aspects. When an individual has a diagnosis of dementia, decision 
making becomes somewhat of a grey area. What is more, persons diagnosed with dementia are 
part of the social environment and their behavior affects also their relatives and surrounding. 
For these reasons, it is important to be able to accurately predict the risk of potential violent 
behavior in these persons and subsequently take a decision about preventing and managing this 
behavior. 
2.4.1 Violence risk assessment 
Currently, there are no official guidelines for violent risk assessment (VRA) in individuals with 
dementia. Although there are instruments to measure potential violence in psychiatric patients 
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and healthy individuals, they may have little use in individuals with dementia. Older people are 
not often perpetrators of serious criminal offences, however, aggression is more common 
among individuals with dementia compared to a healthy population of the same age.130–132 
Cases of homicides involving patients with dementia have been described in the literature, 
mostly as a consequence of delusional believes associated with the victim (e.g. the imposter 
syndrome).133–138 Furthermore, gradual impairment of executive functions139,140 and 
visuospatial processing141 can make it difficult for this group of individuals to handle firearm 
properly. Therefore, if the individuals with dementia have access to the firearm, they may cause 
unintentional injuries and deaths. Moreover, there are studies showing that individuals with 
dementia may have an increased risk of suicide,142 particularly within the first three months 
after the dementia diagnosis.143 In Sweden, people own firearm mostly for the purpose of 
hunting144 and this carries an important social and personal meaning. For this reason, the 
decision about removing a firearm (analogously to losing a driving license) may lead to 
decrease of activity, social isolation and add to overall stigma associated with the diagnosis of 
dementia.145 Additionally, the fear of having the firearm removed from patients’ possession 
can discourage help seeking behavior and delay diagnosis.  
2.4.2 Treatment of BPSD 
Non-pharmacological treatments (NPT) of BPSD include behavioral, environmental and 
caring support interventions. Numerous guidelines recommend NPT as the first line strategy 
of support unless acute treatment is needed.146 Although some of the interventions such as 
family caregiver interventions show higher efficacy than pharmacological treatment, there are 
numerous challenges in introducing them into standard care such as lack of training, time and 
reimbursement for implementation among others.34 Research stresses the importance of 
developing strategies supporting caregiver-recipient relationship. Individuals with spousal 
carers decline more slowly.147 Additionally, a close caregiver-recipient relationship had a 
comparable effect on cognitive decline to that seen with acetylcholinesterase inhibitors.147,148 
Antipsychotics are still a commonly used treatments to alleviate aggression and psychosis.149  
However, their benefits may be observed only among those patients who tolerated the 
medications.150 The use of atypical antipsychotics in dementia is controversial because of 
numerous studies showing that APD treatment may lead to serious side effects including 
death.151 On the other hand, there are data suggesting that this association does not persist after 
adjusting for neuropsychiatric symptoms,152 use of restraints or other factors like severity of 
dementia.153,154  A novel antipsychotic, pimavanserin, showed promise in recent clinical trial.155 
The efficacy of pharmaceutical treatments for other BPSD is also still limited. Serotonergic 
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antidepressants are a popular treatment option for mood disorders, but a recent Cochrane meta-
analysis found little evidence that they are beneficial in treating depression in individuals with 
dementia.156 Pharmacotherapy of apathy includes cholinesterase inhibitors, memantine, 
antidepressants, APDs, and psychostimulants, however all have shown mixed or no success in 
treating apathy in Alzheimer's disease.157–159 Melatonin, trazodone, benzodiazepines, Z-drugs 
(zolpidem, zopiclone, and zaleplon), and the ramelteon are all common sleep aids.159 Other 
treatment possibilities include antihistaminergic drugs, herbal remedies, and antidepressants.159 
A Cochrane meta-analysis of the efficacy of pharmacotherapies for sleep disruptions in 
dementia found a scarcity of data on the subject.160 
In Sweden, risperidone is the only antipsychotic recommended for short-term treatment (up to 
6 weeks) of long-term aggression in individuals with dementia who harm themselves or others. 
Additionally, antidepressants (SSRI), benzodiazepines (oxazepam), hypnotics (clomethiazole) 
and memantine are used to manage the symptoms.161,162 A recent study showed that these 
medications are regularly prescribed to individuals with dementia in Sweden.163  
Questions have been raised about the ethics of these pharmacological approaches in the 
management of challenging behaviors. This is due to several reasons including whether it is 
ethical to give medication to people who are unable to give informed consent or even state their 
objection (e.g. drugs hidden in the food). Moreover, the association with caregiver workload 








The overall aim of the thesis is to obtain a comprehensive understanding of different factors 
associated with treatment and mortality of individuals with Behavioral and psychological 




1. To characterize BPSD in individuals with different dementia diagnoses (Study 1). 
 
2. To analyze the association between unmet needs and BPSD in individuals with 
different dementia diagnoses (Study 2). 
 
3. To assess all-cause mortality of individuals with dementia treated with typical and 
atypical antipsychotic drugs (APDs) (Study 3). 
 
4. To describe firearm ownership in individuals with dementia in Sweden and examine 
which characteristics are explaining physicians’ decision to report a person to the 





4 MATERIALS AND METHODS 
 
The Thesis includes four cross-sectional observational studies based on data from five Swedish 
registries: The Swedish registry for cognitive/dementia disorders (SveDem), the Swedish 
Behavioral and psychological symptoms of dementia Registry (BPSD), the Swedish Prescribed 
Drug Registry (SPDR), the Swedish Cause of Death Registry (CODR), and the Swedish 
National Patient Registry (NPR). Individuals were identified and data was merged using a 
personal identity number (personnummer). Below is a brief description of the data sources, 
primary variable definitions, research samples, and statistical methods used. 
 
4.1 THE SWEDISH REGISTRY FOR COGNITIVE/DEMENTIA DISORDERS 
(SVEDEM) 
 
SveDem is a Swedish national quality-of-care registry that was formed in 2007 with the goal 
of registering all people in Sweden who have been diagnosed with dementia.165 Individuals are 
enrolled to SveDem by their main care physician, a memory clinic, or nursing homes. SveDem 
now covers 78 percent of all primary care facilities, 100%of memory clinics, and 86 
municipalities, with 97 570 unique patients registered.166 The registry collects information on 
the patients' sociodemographic factors, such as age, gender, and living arrangements, as well 
as clinical (such as dementia type and severity, e.g., Mini-Mental State Examination  (MMSE) 
scores)167 and medicine prescriptions, e.g. antidementia, psychotropic and cardiovascular 
medication. Information is collected during baseline registration and at follow-ups 
(approximately annually).165 Nine types of dementia diagnoses are registered in SveDem: 
early- and late-onset AD, Mixed, VaD, DLB, PDD, FTD, unspecified dementia (clinical 
examination to determine dementia type was not carried out or was difficult to specific the 
type) (UNS), and other dementia types (various dementia disorders, e.g. corticobasal 
degeneration, normal pressure hydrocephalus). Clinicians are instructed to use the 10th revision 
of the International Classification of Diseases (ICD-10).  Additonally, the McKeith criteria are 
used for DLB,168 the Lund-Manchester criteria for FTD169 and the Movement Disorder Society 
Task Force criteria for PDD.170  See Religa et al. for a more complete discussion of 





4.2 THE SWEDISH BPSD REGISTRY 
 
The Swedish BPSD registry was launched in 2010 with the goal of improving the quality of 
care for people with BPSD and achieving a nationwide standard of care across Sweden.173 Until 
December 2019, a total of 73 585 individuals were registered in the BPSD registry. The 
estimated coverage of individuals with dementia residing in nursing homes was estimated to 
be about 40%.173 The registration most commonly takes place in long-term care facilities, but 
the registry is used increasingly also in community and in short-term care facilities. The registry 
contains information about BPSD, the current medical therapy and a checklist for possible 
causes of BPSD.174 The Neuropsychiatric Inventory-Nursing Home Version (NPI-NH)10 is 
used to assess BPSD, and it contains twelve categories of BPSD: delusions, hallucinations, 
agitation/aggression, depression/dysphoria, apathy, elation/euphoria, anxiety, disinhibition, 
irritability, aberrant motor behavior, sleep and night-time behavior changes and  appetite and 
eating abnormalities.27  
 
4.3 SWEDISH PRESCRIBED DRUG REGISTRY (SPDR) 
 
SPDR was established in 2005 and covers the whole Swedish population. It includes 
information on drug dispensation from pharmacies.175 It also includes basic sociodemographic 
information (age, sex), type of practice and profession of prescriber, as well as complete 
information on the dispensation (substance name, ATC code, date of prescribing and 
dispensing), dosage and expenditures.175 The registry does not cover medicines that do not 
require a prescription or are used in hospital settings.176 
 
4.4 SWEDISH CAUSE OF DEATH REGISTRY (CODR) 
 
CODR has been accessible electronically since 1952 and is largely utilized in Sweden to 
estimate overall and specific mortality.177 The whole Swedish population is covered in CODR. 
CODR data comes from medical death certificates, which must be completed within three 
weeks of a patient's death by a physician. The register includes information on the date, place 
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(e.g. hospital, nursing home), conditions that contributed to death and underlying causes of 
death according to the ICD coding.  
 
 
4.5 SWEDISH NATIONAL PATIENT REGISTRY (NPR) 
 
NPR has been collecting statistics on inpatient somatic and psychiatric care since 1964 reaching 
its complete coverage in 1987.178 Four types of information are included in the registry: patient-
related data (e.g. age, sex), caregiver data (hospital and department), administrative data 
(admission and discharge date), and medical data (diagnoses according to the ICD system).  
 
4.6 DEFINITIONS AND VARIABLES TRANSFORMATIONS 
 
4.6.1 BPSD 
Assessments of BPSD were performed at the first entry to the BPSD registry using the NPI-
NH,27 based on information reported by a caregiver familiar with the individual's behavior. 
First, the frequency of symptoms is graded on a scale of 1 to 4 (1: occasionally, 2: less than 
once a week, 3: very frequently, 4: more than once a day). Second, the severity of the behavior 
is classified as: 1: mild, 2: moderate, or 3: severe. The NPI-NH assigns a value between 1 and 
12 to each category by multiplying the frequency and severity scores. The total NPI score is 
computed by summing up all of the categories' scores with a maximum of 144 points. Scores 
of four or more in a given category are considered clinically significant.179 BPSD were used as 
an outcome in studies 1 and 2. 
4.6.2 Dementia 
All dementia diagnoses registered by SveDem were included in Studies 1-2. In Studies 2-4, 
individuals with "other dementia" were omitted from the study. Early-onset and late-onset AD 
were grouped together as AD in all studies. Individuals diagnosed with DLB and PDD were 
grouped together as “Lewy body dementia” (LBD) in Studies 1,2, and 4. In addition, all studies 
included MMSE scores at the time of dementia diagnosis, which were obtained from SveDem 




In all studies, the use of medication was binarily defined as users and non-users. We used the 
following sources to extract data regarding drug’s prescription or dispensation: SveDem (Study 
1 and 4), the BPSD registry (Study 1 and 2) and SPDR (Study 3). 
 In the SveDem registry, each patient’s current medication prescription is recorded at the time 
of diagnosis with the possible answers ‘yes’/‘no’/‘do not know’. The following medications 
are recorded in the registry: analgesics, antipsychotics, anxiolytics, hypnotics, antidepressants, 
acetylcholinesterase inhibitors (AChEI) and N-Methyl-D-aspartate (NMDA) receptor 
antagonist. 
In the BPSD registry, information about medical treatment is collected at the time of BPSD 
assessment with the possible answers ‘yes’/‘no’/‘do not know’. Specifically, the Anatomical 
Therapeutic Chemical (ATC) codes for the following medications were recorded: analgesics, 
antipsychotics (N05A), anxiolytics (N05B), hypnotics (N05C), antidepressants (N06AA), 
acetylcholinesterase inhibitors (AChEI) (N06DA) and N-Methyl-D-aspartate (NMDA) 
receptor antagonist (N06DX).  
For Study 3, information about APD dispensation at dementia diagnosis was extracted from 
SPDR. We used the following Anatomical Therapeutic Chemical Classification System codes 
(see: http://www.whocc.no/atc_ddd_index) for antipsychotics classes to classify them into 
typical and atypical APD: typical: N05AA phenothiazines with aliphatic side-chain, N05AB 
phenothiazines with piperazine structure, N05AD butyrophenone derivatives, N05AF 
thioxanthene derivatives; atypical: N05AE indole derivatives, N05AH diazepines, oxazepines, 
thiazepines, and oxepines, and N05AX other antipsychotics. In this study, typical and atypical 
APD dispensation at the time of dementia diagnosis was used as an exposure.   
4.6.4 Other covariates 
Age, sex and living arrangements (living alone in ordinary housing, with somebody else in 
ordinary housing, or in a long-term care facility) were extracted from SveDem for all 
individuals.  Age and sex were used as covariates in all studies, while living arrangements were 
considered only in Studies 3 and 4. The Charlson Comorbidity Index (CCI) was calculated by 
extracting ICD-10 codes from the NPR for chronic diseases other than dementia.180 CCI 
contains 19 diseases including diabetes with diabetic complications, congestive heart failure, 
peripheral vascular disease, chronic pulmonary disease, mild and severe liver disease, 
hemiplegia, renal disease, leukaemia, lymphoma, metastatic tumor, and acquired 
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immunodeficiency syndrome (AIDS), each of which was weighted according to their potential 
influence on mortality. The CCI score was used as a covariate in Study 1. 
4.6.5 All-cause mortality 
All-cause mortality was used as an outcome in Study 3. The outcomes were defined based on 
mortality as recorded in the CODR. The death of a person was counted if a valid record in the 
CODR existed (date of death dated after the study baseline). 
4.6.6 Firearm status 
SveDem contains the information about the firearm status of the individuals as well as whether 
the person was reported to the police as unsuitable to possess the firearm. The latter was used 
as an outcome in Study 4. 
4.6.7 Unmet needs 
To assess the relationships between unmet needs and different BPSDs, the checklist for 
possible causes of BPSD was performed at the first registration to BPSD registry (Panel 1). 
The checklist's items were chosen based on clinical experience. A caregiver assesses the unmet 
needs based on their observations of the individual. The elements in the checklist can be rated 
as "yes" or "no." Items marked with a "no" indicate that there are unmet needs. For example, 
the question for the item "Pain" is "does the individual appear to be free of suffering?" and the 
answer "no" indicates pain. The total unmet needs score was computed by adding the number 
of items on the checklist on which an individual answered "no," resulting in a score ranging 
from 0 to 14. Individual’s unmet needs as well as the total unmet needs score were used as an 
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Normal blood Pressure 
Normal blood sugar 
 
4.7 STUDY SAMPLES 
For Studies 1-2, data from SveDem was merged with data from the BPSD registry (individuals 
registered between 2007 and 2015). After merging the data, 13,413 individuals registered in 
both registries were identified. The cohort included only individuals residing in long-term care 
facilities. After excluding individuals residing in a community and applying other exclusion 
criteria, we reached a sample size of 10,405 individuals (Figure 1). 
In Study 3, we included 58,412 individuals with dementia that were registered in SveDem until 
December 31st, 2015. SveDem was merged with SPDR, CODR, and SNP and exclusion criteria 
were applied reaching a total of 56,048 individuals included in the final sample (Figure 1). 
For Study 4, we used the information about individuals registered in SveDem between May 
2007 to December 31st, 2016 (n = 69,100). After applying the exclusion criteria, we obtained 
the final study sample comprising of 65,717 individuals. For the main analyses, only 




Figure 1. The analytical samples extracted for the studies. 
 
 
AD - Alzheimer Disease, Mixed - Mixed Dementia, VaD – Vascular dementia, DLB – 










4.8 STATISTICAL METHODS 
 
All analyses were undertaken in R version 3.6.0 (Foundation for Statistical Computing, Vienna, 
Austria).181 In all studies, continuous variables were summarized as mean and standard 
deviation (SD) or median and interquartile range, while categorical variables were summarized 
as the number of individuals and percentages. In univariate comparisons, the independent-
samples t-test and one-way ANOVA were used to compare continuous variables, while Fisher-
exact and the χ2 test were used to compare categorical variables. Specific methods used in 
individual studies are described below and in Table 1. For all studies a p-value <0.05 
(corresponding to 95% CI) was considered statistically significant.  
Study 1 
Multivariate logistic regression was used to estimate the odds ratios (ORs) and 95% confidence 
intervals (CIs) of having a clinically significant BPSD (NPI score > 3 in each category) 
compared to no symptom in each diagnosis compared to AD. The studies were then performed 
with each diagnosis as a control group. All models were adjusted for age, sex, MMSE and time 
between SveDem and BPSD registries.  
Study 2 
To find an association between the total unmet needs score and the total NPI score, we first 
built a linear regression model between the total unmet needs score as an independent variable 
and the total NPI score as an outcome in the whole cohort. This model was adjusted for the 
type of diagnosis, age, gender, MMSE score and time between registration to SveDem and the 
BPSD registry. Next, we stratified the cohort by the type of diagnosis, and performed linear 
regression analyses in each diagnostic group, adjusting for age, gender, MMSE score and time 
between time between entry to SveDem and BPSD registries. Finally, in each model, variable 
importance was estimated with a dominance analysis (DA).182  
 
Secondary analyses 
The relationship between specific unmet needs and BPSD was investigated in secondary 
analyses. We used multivariate logistic regression analysis to estimate Odds ratios (OR) and 
95% Confidence Intervals (CIs) for the relationship between the individual unmet needs and 
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clinically significant BPSD (ref. no symptom). Variable selection was performed in 5 steps, as 
described below. 
Step 1. To select unmet needs for multivariate logistic regression analysis, we first applied 
univariable logistic regression analysis with each independent variable (unmet need) and each 
BPSD separately. Variables with p < 0.05 were selected for the next step. 
Step 2. We fitted multivariate logistic regression models containing all covariates identified for 
inclusion in Step 1. Each model was adjusted for age, gender, MMSE score, and time between 
registration to SveDem and BPSD registries. 
Step 3 and 4. Variables with p > 0.05 in multivariate logistic regression analysis were removed 
from the models.  
Step 5. All multivariate models were evaluated with Akaike information criterion (AIC).  
Because of the low number of cases, we excluded the following unmet needs from the analyses: 
abnormal temperature, abnormal pulse, abnormal breathing. Additionally, to avoid conflicting 
exposer with the outcome, we excluded the following variables: not sufficient food and 
sleeping impairment in models for appetite and eating abnormalities and sleep and night-time 
behavior changes, respectively. 
Study 3 
The median survival time was calculated using the Kaplan-Meier method, and the median 
length of follow-up was calculated using the reverse Kaplan-Meier method.183 The 
proportionate hazard assumption for the main predictors was verified by plotting the 
Schoenfeld residuals as a function of time and testing the hypothesis of a zero slope. Following 
that, separate Cox multivariate regression models were generated for the entire cohort and 
stratified by dementia type to evaluate the risk of mortality related with APD usage compared 
to nonuse. These models yielded crude and adjusted hazard ratio (HR) values, as well as 
associated 95% confidence intervals (CIs). Age at dementia diagnosis, MMSE, CCI, sex, and 
living arrangement (living alone in ordinary housing, with somebody else in ordinary housing, 
or in a long-term care facility) were all included into the final model. Finally, we repeated the 
analysis to compare users of typical and atypical APDs.  
Due to violation of the assumption for proportional hazard in VaD, interactions with time were 
used to model the association in this diagnosis. To this end, we inspected residual plots and 
divided data into two epochs of the first 360 days and greater than that. Separate hazard 
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functions were fitted for each time-band. To this end, we inspected residual plots and divided 
data into two epochs of the first 360 days and greater than that. Separate hazard functions were 
fit for each time-band. Data were analysed with the Survival Package for R statistical 
software.184 
Study 4 
The odds ratios (ORs) and 95% confidence intervals (CIs) of the association between 
preselected factors and the outcome were estimated using multivariable logistic regression. 
Dementia subtype, gender, age, MMSE score (very severe: 0–10, moderate severe 11–18, 
moderate 19–23, mild 24–30), hypnotics, antipsychotics, anxiety suppressors, antidepressants, 
N-Methyl-D-aspartate receptor antagonist, acetylcholinesterase inhibitors, vascular 
medication, living arrangement (living alone in ordinary housing, with somebody else in 
ordinary housing, or in a long-term care facility), and diagnosing unit (primary care, memory 
clinic) were assessed as potential predictors of the outcome, which was being reported to the 
police as unsuitable to own firearm.  
Discrimination ability of the model was evaluated by bootstrapped area under the receiver 
operating characteristic curve (AUC).185 Finally, variable importance was estimated with fully 















4.9 ETHICAL CONSIDERATIONS 
 
In epidemiology and public health practice, ethical considerations frequently revolve around 
the responsibility of health professionals' responsibility to obtain and utilize scientific 
information in order to preserve and restore public health while protecting individual rights.187 
Potential social advantages must frequently be weighed against risks and potential costs to 
people and groups, such as stigmatization and violations of privacy of privacy. Although the 
hazards offered by epidemiologic research are often small in comparison to those posed by 
clinical trials and other experimental investigations, participants in epidemiologic studies may 
face a loss of privacy or stigmatization. The Council of International Organizations of Medical 
Sciences issued international criteria for ethical evaluation of epidemiology studies.188 The 
institutional review board system, informed consent, avoiding and disclosing conflicts of 
interest, minimizing risks and providing benefits,  and the obligations to communities are the 
issues highlighted in ethics guidelines. 
The goal of research ethics committees is to guarantee that studies involving human research 
subjects are planned in accordance with applicable ethical standards and that the participants' 
rights and welfare are respected. Human-subjects assessment by such committees guarantees 
that research has a good balance of potential benefits and risks, that participants are selected 
equitably, and that informed consent processes are acceptable. The regional ethical review 
board in Stockholm, Sweden, authorized all operations involving human subjects/patients, with 
the following ethical numbers: 2015/2291-31/5 (Studies 1 and 2) and 2015/2232-31 (Studies 3 
and 4). In addition, part of my PhD research was dedicated to recruiting participants for the 
multicenter European project Remote Assessment of Disease and Relapse-Alzheimer’s disease 
(RADAR-AD), which investigated the potential of mobile technology in enhancing the quality 
of care for people with Alzheimer’s disease.189 We received a separate ethical approval for this 
study with the number 2020-03497. According to the protocols in SveDem and BPSD registry, 
individuals with dementia and their relatives are provided oral and written information about 
the goals of the studies and can refuse to participate. The authors assert that all procedures 
contributing to this work comply with the ethical standards of the relevant national and 
institutional committees on human experimentation and with the Helsinki Declaration of 1975, 
as revised in 2008. To avoid the conflicts of interest, all researchers involved in the study 
disclosed their financial interests and funding sources before publishing their findings. 
In epidemiologic studies of vulnerable groups, minimizing risks and possible harms while 
optimizing potential benefits is crucial. The rigorous protection of the anonymity of 
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participants' health information is an important strategy for public health researchers to prevent 
possible harms and hazards to them in epidemiologic studies. To ensure the confidentiality of 
the participants' health information, rigorous measures were implemented. Personal identifiers 
were removed from data. After the ethical application had been accepted by the ethical 
committee, the data were anonymized and it is not possible to reverse the anonymization. 
Additionally, data were solely evaluated at the group level, with no subject-level analysis. The 
potential benefits of our studies are mostly social in nature. Although participants may not gain 
immediate benefits as a result of their involvement in the study, our findings aid in the gathering 
of new knowledge regarding the parameters linked to improved quality of life of individuals 
with dementia. The underlying objective of our study is to get a comprehensive understanding 
of the factors associated to BPSD. Registry-based data provide substantial benefit by enabling 
merging several different registries together as well as large number of registered individuals. 
We took an active role in popularizing the finding of our research. For example, we presented 
our research in ForskarFredag (Researchers' Friday). The event is organized by the non-profit 
organization Vetenskap & Allmänhet in Sweden (Public & Science). Additionally, results of 
the Study 3, were published in Swedish medical journal Läkartidningen (Läkartidningen 19–
20/2019; “Antipsykotika förknippade med ökad mortalitet vid demens”). Results of the Study 
4 were disseminated as a press release. I was also responsible for organizing and moderating 
webinar “Technology in Dementia: promises and barriers identified by the RADAR-AD 
project”, where we discussed details concerning RADAR-AD project (project not included in 





5.1 BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ARE FREQUENT IN 
ALL TYPES OF DEMENTIA (STUDY 1) 
 
In Study 1, we found that 75% of all individuals with dementia had at least one clinically 
significant BPSD, with the most common being aberrant motor behavior, agitation/aggression 
and irritability. The frequencies of BPSD in each diagnosis are presented in Figure 2. The 
multivariate logistic regression analyses showed that, compared to AD, individuals with VaD 
had higher risk of apathy but lower risk of agitation/aggression, anxiety, aberrant motor 
behavior; individuals with Mixed dementia had lower risk of clinically significant anxiety and 
aberrant motor behavior; individuals with DLB had higher risk of delusions and hallucinations 
and lower risk of elation/euphoria and irritability; individuals with PDD had higher risk of 
hallucinations but lower risk of agitation/aggression and disinhibition, individuals with FTD 
had higher risk of apathy, disinhibition, appetite and eating abnormalities as well as lower risk 
delusion, hallucinations, depression/dysphoria; individuals with UNS had lower risk of 
delusion, agitation/aggression, depression/dysphoria, anxiety, irritability, aberrant motor 
behavior, sleep and night-time behavior (Table 1). Short summary of comparisons between 

































Table 1. Odds ratios (OR) and 95% confidence intervals (CI) of the association between dementia type and BPSD with the reference to AD 
in individuals residing in long-term care facility. 
AD - Alzheimer Disease, Mixed - Mixed Dementia, VaD – Vascular dementia, DLB – Dementia with Lewy Bodies, PDD – Parkinson’s disease 
dementia, FTD – Frontotemporal dementia, UNS – Unspecified dementia. Model adjusted for age, sex, MMSE and time between registration to 
SveDem and BPSD registry.
 
VaD  Mixed DLB PDD FTD UNS 
 
OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value 
Delusions 
0.95 (0.82-1.11) 0.542 0.91 (0.78-1.06) 0.234 1.71 (1.25-2.33) 0.001 1.35 (0.85-2.1) 0.185 0.44 (0.27-0.68) <0.001 0.87 (0.77-1) 0.044 
Hallucinations 
0.83 (0.69-1.01) 0.066 0.94 (0.78-1.13) 0.54 5.94 (4.31-8.2) <0.001 4.47 (2.86-6.95) <0.001 0.5 (0.27-0.85) 0.016 1.01 (0.86-1.18) 0.93 
Agitation/Aggression 
0.85 (0.73-0.98) 0.029 1.01 (0.87-1.17) 0.905 0.84 (0.61-1.16) 0.291 0.46 (0.28-0.75) 0.002 0.97 (0.67-1.41) 0.871 0.85 (0.75-0.96) 0.011 
Depression/Dysphoria 
0.94 (0.8-1.1) 0.465 0.93 (0.79-1.09) 0.361 1.01 (0.69-1.45) 0.964 0.69 (0.39-1.16) 0.181 0.57 (0.38-0.85) 0.007 0.83 (0.72-0.95) 0.007 
Elation/Euphoria 
0.9 (0.69-1.18) 0.463 0.89 (0.68-1.16) 0.395 0.32 (0.11-0.71) 0.014 0.79 (0.3-1.69) 0.58 1.25 (0.72-2.05) 0.405 0.89 (0.7-1.11) 0.307 
Anxiety 
0.85 (0.73-0.98) 0.031 0.82 (0.71-0.96) 0.012 0.83 (0.58-1.16) 0.282 0.64 (0.37-1.06) 0.097 0.73 (0.49-1.07) 0.11 0.75 (0.66-0.85) <0.001 
Apathy 
1.21 (1.03-1.42) 0.023 1.04 (0.88-1.22) 0.684 0.87 (0.58-1.26) 0.471 0.89 (0.5-1.49) 0.678 1.54 (1.06-2.22) 0.022 1.09 (0.94-1.25) 0.256 
Disinhibition 
1.03 (0.87-1.22) 0.714 1.02 (0.86-1.21) 0.816 0.71 (0.46-1.05) 0.097 0.4 (0.19-0.74) 0.007 1.52 (1.03-2.2) 0.03 0.97 (0.83-1.12) 0.683 
Irritability 
0.94 (0.81-1.08) 0.381 1.08 (0.93-1.24) 0.322 0.67 (0.47-0.93) 0.018 0.65 (0.4-1.04) 0.081 0.69 (0.48-0.98) 0.042 0.83 (0.73-0.95) 0.005 
Aberrant motor 
behavior 0.66 (0.58-0.76) <0.001 0.75 (0.66-0.86) <0.001 0.75 (0.55-1) 0.053 1.12 (0.74-1.68) 0.594 0.83 (0.59-1.15) 0.257 0.73 (0.65-0.82) <0.001 
Sleep and night-time 
behavior changes 0.92 (0.78-1.08) 0.317 0.91 (0.77-1.07) 0.267 0.98 (0.67-1.4) 0.917 0.66 (0.37-1.13) 0.148 0.82 (0.51-1.26) 0.381 0.82 (0.71-0.95) 0.008 
Appetite and eating 
abnormalities 1.08 (0.92-1.27) 0.33 1.02 (0.87-1.2) 0.809 0.92 (0.62-1.32) 0.649 0.63 (0.34-1.07) 0.109 1.84 (1.27-2.63) 0.001 1 (0.87-1.15) 0.998 
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Table 2. Summary of the differences in BPSD in individuals residing in long-term facility based on logistic regression analyses. 
Diagnosis > ref - Diagnosis Less than ref: Diagnosis < ref - Diagnosis More than ref; AD - Alzheimer Disease; Mixed - Mixed Dementia; VaD – Vascular 




AD VaD Mixed DLB PDD FTD UNS 





Mixed < FTD 
DLB<AD, Mixed, VaD, FTD, 
UNS 
 PDD<FTD FTD>AD, Mixed, VaD, DLB, PDD, UNS UNS>AD, DLB;  
UNS<FTD 
Hallucinations AD< FTD;  
AD>DLB, PDD 
VaD>DLB, PDD;  
 
Mixed> DLB, PDD;  
Mixed < FTD 
DLB<AD, Mix, VaD, FTD, 
UNS 
PDD<AD, Mixed, VaD, FTD, 
UNS;   
FTD>AD, Mixed, DLB, PDD, UNS UNS>DLB,PDD;  
UNS<FTD 






DLB<PDD PDD>AD, Mixed, VaD, DLB, 
FTD, UNS 
FTD<PDD UNS>AD, Mixed;  
UNS<PDD 
Depression/Dysphoria AD<FTD, UNS VaD<FTD   Mixed<FTD  DLB<FTD    FTD>AD, Mixed, VaD, DLB UNS>AD 
Elation/Euphoria AD<DLB VaD<DLB Mixed<DLB DLB>AD, Mixed, VaD, FTD, 
UNS 
  FTD<DLB UNS<DLB 
Anxiety AD<Mixed,VAD 
UNS 
VaD<AD AD>Mixed    
 
  UNS>AD 








DLB>FTD  PDD>Mixed, VaD, FTD, UNS FTD<AD, Mixed, DLB, PDD, UNS UNS<PDD; 
UNS>FTD 
Irritability AD<DLB, FTD, 
UNS 
 Mixed<DLB, PDD, 
FTD, UNS 
DLB>AD, Mixed PDD>Mixed   FTD>AD, Mixed UNS>AD, Mixed 
Aberrant motor behavior AD<Mixed, VaD, 
UNS 
VaD>AD, PDD Mixed>AD   PDD<VaD 




Sleep and night-time 
behavior changes 
AD<UNS   
  
    UNS>AD 
Appetite and eating 
abnormalities 
AD>FTD VaD>FTD Mixed>FTD DLB>FTD PDD>FTD FTD<AD, Mixed, VaD, DLB, PDD, UNS UNS>FTD 
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5.2 UNMET NEEDS ARE RELATED TO INCREASED RISK OF BPSD (STUDY 
2) 
 
The results of Study 2 showed that pain was the most common unmet need (29.1%) in 
individuals with dementia. This was followed by sleeping disturbances (15.3%), abnormal 
sight (15.1%) and abnormal hearing (15.0%) (Table 3). Linear regression models revealed an 
association between the unmet needs score and total NPI scores (beta=5.32, t=34.86, p<0.001) 
(Table 5). The results were similar when analyses were performed in each diagnosis separately. 
DA showed that the total unmet needs score had a general dominance over other variables in 
the model. The average contribution of each predictor to an overall model fit is presented in 
Table 4. Additionally, in the secondary analyses, we found that unmet needs manifest in a 
variety of behaviors. Pain, sleeping disturbances and social isolation were commonly 






























The data are presented as n (%). AD - Alzheimer Disease, Mixed - Mixed Dementia, VaD – Vascular dementia, LBD - Lewy body dementia, FTD – 
Frontotemporal dementia, UNS – Unspecified dementia. To assess differences between group we used Pearson Chi-Square test or Fisher’s exact test.  
 
 
Total AD Mixed VaD LBD FTD UNS P.value 
Insufficient Food 1124 (11) 389 (11,2) 183 (11,5) 171 (10,2) 39 (11,1) 18 (9,1) 324 (11,1) 0.787 
Insufficient Fluids 790 (7.8) 281 (8.1) 132 (8.3) 116 (6.9) 34 (9.7) 10 (5.1) 217 (7.4) 0.211 
Abnormal Urine 494 (4.9) 142 (4.1) 77 (4.9) 93 (5.6) 22 (6.3) 5 (2.5) 155 (5.3) 0.047 
Abnormal Faeces 894 (8.8) 284 (8.2) 124 (7.8) 145 (8.7) 45 (12.9) 21 (10.7) 275 (9.4) 0.211 
Abnormal Sight 1534 (15.1) 439 (12.7) 250 (15.8) 309 (18.5) 55 (15.7) 15 (7.6) 466 (16) <0.001 
Abnormal Hearing 1532 (15) 429 (12.4) 270 (17) 291 (17.4) 28 (8) 15 (7.6) 499 (17.1) <0.001 
Pain 2944 (29.1) 962 (28) 463 (29.4) 496 (29.8) 94 (27) 53 (26.9) 876 (30.2) 0.345 
Social isolation 779 (7.7) 244 (7.1) 133 (8.4) 144 (8.6) 29 (8.3) 17 (8.7) 212 (7.3) 0.279 
Sleeping problems 1556 (15.3) 542 (15.7) 264 (16.7) 277 (16.6) 52 (14.9) 24 (12.2) 397 (13.6) 0.029 
Abnormal temperature 29 (0.3) 5 (0.1) 9 (0.6) 5 (0.3) 3 (0.9) 1 (0.5) 6 (0.2) 0.026 
Abnormal pulse 186 (1.8) 53 (1.5) 36 (2.3) 40 (2.4) 5 (1.4) 2 (1) 50 (1.7) 0.208 
Abnormal breathing 872 (8.7) 250 (7.3) 149 (9.5) 148 (9) 56 (16.1) 12 (6.1) 257 (8.9) 0.007 
Blood Pressure 450 (4.5) 125 (3.7) 71 (4.5) 130 (7.9) 12 (3.5) 8 (4.1) 104 (3.6) <0.001
 




Table 4. Dominance analysis and Linear Regression model for the association between variables used in the model and Neuropsychiatric 










NPI – Neuropsychiatric Inventory, AD - Alzheimer Disease, Mixed - Mixed Dementia, VaD – Vascular dementia, LBD –Lewy Body Dementia, 
FTD – Frontotemporal dementia, UNS – Unspecified dementia, MMSE - Mini-Mental State Exam at the time of diagnosis, Time between 
registrations – days between entry to SveDem and BPSD registry, *multiplied by 1000.
 Linear regression model Dominance analysis 
 Coefficients Standard Error t Stat p Weighting* (rank) 
Total unmet needs 4.84 0.15 33.36 <0.001 92.8 (1) 
Diagnosis, ref:AD     3 (5) 
     Mixed -1.55 0.57 -2.71 0.007  
     VaD -1.9 0.57 -3.33 0.001  
     LBD -0.86 1.07 -0.80 0.424 
      FTD 0.13 1.42 0.09 0.929 
     UNS -2.06 0.51 -4.06 <0.001 
Male (ref: Female) 0.69 0.41 1.70 0.09 1 (6) 
Age -0.41 0.03 -15.64 <0.001 16 (2) 
MMSE  -0.31 0.04 -8.05 <0.001 4.8 (3) 




5.3 APDS ARE ASSOCIATED WITH INCREASED MORTALITY RISK IN 
INDIVIDUALS WITH DEMENTIA (STUDY 3) 
 
In the whole sample, 4% (n = 2526) of the individuals had an APD prescription: 602 had only 
typical APDs,1833 had only atypical APDs and ninety-one individuals had both typical and 
atypical APDs prescribed. There were differences in APD use between the different dementia 
diagnoses. Among individuals receiving APDs, typical APD use was lowest in individuals with 
LBD (13%), followed by other (23%), VAD (24%), FTD (24%), UNS dementia (25%), AD 
(26%), and mixed dementia (32%). Atypical use was lowest in Mixed (68%), followed by AD 
(74%), UNS dementia (75%), VAD (76%), FTD (76%), other (77%), and LBD (87%).  
Use of typical and atypical APDs was associated with increased mortality risk compared with 
no APD use in the entire cohort [HR (95% CI)].  Typical APDs increased the risk of death by 
1.4 (1.2-1.5) and atypical APDs by 1.4 (1.3-1.5) (adjusted for sex, age, MMSE, CCI, and form 
of residency)]. Statistically significant associations between APD use and increased risk of 
mortality compared with non-APD use were also found when the cohort was stratified by the 
















Figure 3. Cox multivariate analyses assessing all-cause mortality risk associated with 




Total- entire cohort; AD – Alzheimer Disease, Mixed – Mixed Dementia, LBD – Lewy body 
dementia, FTD – Frontotemporal dementia, UNS – Unspecified dementia, APD - 
Antipsychotic; Adjusted for Age, Gender, MMSE, CCI, Living. VaD: Assuming proportional 
hazard; Typical and Atypical compared to no APD; Typical1 compared to atypical APD, Total 









5.4 ENVIRONMENTAL, PATIENT-RELATED AND SYSTEM FACTORS ARE 
ASSOCIATED WITH INCREASED RISK OF BEING REPORTED TO THE 
AUTHORITY AS UNSUITABLE TO OWN A FIREARM (STUDY 4) 
 
We identified 1,823 (3.4%) individuals with dementia who owned a firearm. Out of those, 346 
individuals were reported to the police by the physicians as unsuitable to own a firearm. 
Additionally, 73 individuals were reported despite the lack of information on their firearms 
status. Compared to individuals with dementia who did not own firearm, firearm owners were 
younger (age < 79 years: 53.4% versus 38.8%), predominantly male (90.4% versus 38.7%), 
living alone (71.5% versus 46.7%), and without assistance of homecare (17.8% versus 33.4%). 
The distribution of other characteristics was similar between the two groups. Almost 19% of 
persons had missing information on the firearm status. 
According to dominance analysis, the most important characteristics used by physicians were: 
1) living arrangement, 2) dementia subtype, 3)APD prescription, 4) diagnosing unit, 5) sex, 
and 6)MMSE score. Somewhat similar, the most important factors in terms of the SC were: 
diagnosing unit (being diagnosed in primary care versus memory clinic, SC = -0.27), followed 
by mild dementia (MMSE 24–30 versus 0–10, SC = -0,25), living arrangements (living with 
someone else in the household versus living alone, SC = 0.23), moderate dementia (MMSE 
19–23 versus 0–10, SC = -0.21), antipsychotics prescription (SC = 0.18), dementia subtype 
(FTD versus AD, SC = 0.18), female gender (SC = 0.18), and hypnotics (SC = 0.17). Of these, 
following predictors were associated with higher odds of being reported to the police as 
unsuitable to possess firearm [OR (95% CI)]: living with someone else in household [1.67 
(1.17–2.38)], hypnotics [1.77 (1.21–2.59)] or antipsychotics [2.42 (1.35–4.35)] prescription, 
being diagnosed with FTD [3.1 (1.56–6.18)], and being a female [1.79 (1.2–2.67)]. On the 
other hand, being diagnosed in a primary care clinic [0.59 (0.44–0.78)] and with mild [0.60 
(0.32–1.13)] or moderate [0.65 0.35–1.22)] dementia were associated with lower odds of being 
reported. The pooled bootstrapped AUC of the model was 0.66.  The full model is presented in 








Table 5. Odds ratios (OR) and 95% confidence intervals (CI) and the relative importance 
indicators (standardized coefficients (SC) and dominance rank (DR) based on the 
standardized general dominance statistic (SGDS)) of the association between predictors 
and being reported to the police as unsuitable to own a firearm. 
 
 OR (95%CI) SC SGDS DR 
Diagnosis  
Alzheimer's Disease Ref Ref 
0.011 2 
Frontotemporal dementia 3.1 (1.56-6.18) 0.180 
Lewy body dementia 0.89 (0.53-1.5) -0.030 
Mixed dementia 1.45 (1.06-2.16) 0.149 
Vascular dementia 1.38 (0.88-2.16) 0.131 
Other 1.59 (0.75-3.36) 0.075 
Unspecified 1.21 (0.83-1.78) 0.080 
Age  
<74 Ref Ref 
0.0026 9 
74-78 1.22 (0.74-2) 0.053 
79-84 1.22 (0.75-2) 0.051 
>84 0.89 (0.51-1.55) -0.074 
Gender 
Female vs Male 1.79 (1.2-2.67) 0.177 0.0084 5 
Mini-Mental State Examination 
Very severe (0-10) Ref Ref 
0.0072 6 
Moderate severe (11-18) 0.97 (0.5-1.9) -0.012 
Moderate (19-23) 0.65 (0.35-1.22) -0.209 
Mild (24-30) 0.6 (0.32-1.13) -0.245 
Living arrangements 
Living alone Ref Ref 
0.0166 1 Nursing Home 2.14 (1.25-3.64) 0.152 
Living with another person 1.67 (1.17-2.38) 0.232 
Diagnosting unit 
Primary care vs. Memory Clinic  0.59 (0.44-0.78) -0.266 0.0094 4 
Daycare 
Yes vs. no 0.87 (0.4-1.89) -0.030 0 14 
Homecare 
Yes vs. no 1.18 (0.86-1.63) 0.063 0.0028 8 
N-Methyl-D-aspartate receptor antagonists 
Yes vs. no 0.94 (0.59-1.5) -0.009 0 14 
Acetylcholinesterase inhibitors 
Yes vs. no 0.91 (0.66-1.27) -0.050 0.002 10 
Vascular drugs 
Yes vs. no 0.84 (0.65-1.08) -0.084 0.0014 12 
Antidepressants 
Yes vs. no 0.74 (0.52-1.06) -0.135 0.0018 11 
Antipsychotics 
Yes vs. no 2.42 (1.35-4.35) 0.184 0.0098 3 
Hypnotics 









6.1 DIFFERENCES AND SIMILARITIES IN BPSD ACROSS SUBTYPES OF 
DEMENTIA (STUDY 1)  
 
We found that BPSD is prevalent across all dementia types, with approximately 75% of all 
individuals having at least one clinically significant BPSD. The most prevalent symptoms were 
abnormal motor behavior, agitation, and irritability. 
AD, VaD, and Mixed 
Aberrant motor behavior, agitation/aggression, and irritability were the most prevalent 
clinically significant symptoms in AD, Mixed, and VaD. We found that individuals with AD 
had a greater risk of anxiety, abnormal motor behavior, and agitation when compared to 
individuals with Mixed and VaD. On the other hand, individuals with VaD exhibited a higher 
risk of apathy than those with AD. The sole difference between individuals with Mixed and 
VaD was a higher risk of agitation/aggression in individuals in Mixed. 
DLB and PDD 
The most common symptoms in DLB were hallucinations, aberrant motor behavior and 
agitation/aggression and in PDD aberrant motor behavior, hallucinations and delusions. 
However, in adjusted analyses apart from a decreased likelihood of agitation/aggression in 
individuals with PDD compared to individuals with DLB, we found no major differences 
between the two diagnoses. Our study demonstrated a greater risk of hallucinations and 
delusions in DLB compared to other diagnoses. Individuals with DLB, on the other hand, 
showed a lower risk of elation/euphoria than those with any other kind of dementia, except for 
PDD. Anxiety and other hyperactivity spectrum symptoms (agitation/aggression, disinhibition, 
and irritability) were less common in those with PDD than in the remaining diagnoses. 
FTD 
The most common symptoms in FTD were aberrant motor behavior, agitation/aggression and 
irritability. Moreover, the highest total NPI score was found in this group of individuals. 
Additionally, in adjusted models, we discovered a higher risk of apathy (except for VaD, PDD, 
and UNS), disinhibition (except for VaD), appetite and eating abnormalities in FTD compared 
to the other dementia diagnoses, as well as a reduced risk of delusions, hallucinations (except 
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for VaD), and depression (except for PDD and UNS). In comparison to DLB, FTD had a 
greater probability of elation/euphoria.  
UNS 
In UNS, abnormal motor behavior, agitation/aggression, and irritability were the most 
prevalent symptoms. Additionally, this group had the lowest total NPI score. This was 
consistent with our findings of a decreased likelihood of numerous symptoms in UNS 
compared to other kinds of dementia. 
General comment 
In our cohort, the most prevalent symptoms were abnormal motor behavior, agitation, and 
irritability, which were found to be common in all dementias. Previous research that included 
individuals in long-term care facilities has similarly found high levels of hyperactive symptoms 
in this study settings.190 However, to our knowledge, this is the first study to indicate that these 
symptoms occur often independent of dementia type. Certain characteristics of the long-term 
care facilities appear to enhance the incidence of BPSD.89 The perception of the environment 
and coping capacities are affected by dementia-related processes.33,34 Hyperactivity symptoms 
in individuals with dementia may be therefore the consequence of greater vulnerability to 
stresses and a higher susceptibility to over- or under-stimulation, which can lead to 
dysfunctional behaviors like agitation or irritability. Additionally, boredom-relieving behaviors 
like as pacing or wandering may be used to compensate for a lack of stimulation, which is 
prevalent in long-term care facilities.92 The finding of BPSD consistency across diagnoses has 
implications for developing cost-effective therapies. Regardless of the underlying condition, 
our findings imply that if resources are limited, attempts to minimize agitation/aggression, 
aberrant motor behavior, and irritability should be prioritized. 
 
6.2 THE ASSOCIATION OF UNMET NEEDS AND BPSD (STUDY 2) 
 
Pain, sleeping problems, impaired hearing and vision were the most prevalent unmet demands. 
Furthermore, we found that an increase in the number of unmet requirements was linked to an 
increase in the overall NPI score, regardless of the type of dementia. Furthermore, the 
dominance analyses revealed that unmet needs contribute more to BPSD than the type of 
dementia, age or gender. In secondary analyses we observed that unmet needs present 
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themselves in a range of behaviors. Pain, sleep difficulties, and social isolation were all linked 
to a variety of symptoms in individuals with dementia. 
General comment 
This and several earlier studies indicate a link between unmet needs and BPSD.29,30,92,191–193  
However, the exact mechanisms behind this association are unknown. Caring for individuals 
with dementia is challenging due to their increasing inability to communicate their needs, 
especially as they move through the disease. 29,30  Therefore, BPSD might be triggered by an 
inability to convey ones’ need or discomfort. Individuals who are understimulated, have pain 
or other sources of discomfort, but are unable to articulate their feelings, may become agitated 
or display other BPSD symptoms.30,92,194–199 Furthermore, unmet needs may trigger a cascade 
of events in which one unmet need leads to another, resulting in BPSD.31 Ignoring the basic 
physiological needs may also lead to dehydration, malnutrition or chronic constipation. 
Constipation in turn has been linked to agitation and anxiety in the past.200,201 BPSD may also 
emerge as a compensation mechanism. For example, internal stimuli may be triggered to 
compensate for a lack of stimulation caused by limited social interaction or sensory 
impairment.193 Additionally, there is a possibility that unmet needs and BPSD share a 
neuropathology. For example, neurodegeneration can result in unmet needs such as sleeping 
difficulties or sensory impairment.202–204 
Clinical guidelines in Sweden recommend non-pharmacological interventions for BPSD before 
implementing drug therapies.  Our findings highlight the need of identifying underlying unmet 
needs in persons with dementia, such as pain, social isolation, sleep, and vision impairment, as 
a cause of behavioral difficulties before administering psychotropic medication. Unmet needs 
constitute potentially modifiable factors contributing to BPSD. The evidence emphasizes the 
potential utility of effective pain therapy, sensory impairment treatment, and non-drug 
therapies in lowering BPSD as well as the use of psychotropic medicines.205–209 Despite the 
paucity of high-quality evidence for sleep disorders therapies, there are some possibilities for 







6.3 TREATMENT WITH ANTIPSYCHOTICS AND MORTALITY (STUDY 3) 
 
APDs were used by 4% of individuals with newly diagnosed dementia and their usage was 
associated with an increased risk of mortality. In individuals with AD, typical APDs were 
associated with similar mortality risk as lack of APDs and only atypical APDs were related to 
a higher risk of mortality. To our knowledge, this has not been previously described. Similar 
to individuals with AD, the higher mortality in individuals with UNS was observed solely with 
atypical APD usage. In individuals with VaD and Mixed, both atypical and typical APDs were 
linked to an increased risk of mortality. In individuals with VAD, we found nonsignificant 
trends showing an increased risk of mortality for typical APD use compared to atypical APD 
usage. In individuals with LBD, we found nonsignificant trends indicating an increased risk of 
death for typical APD use compared to atypical use and no APDs at all. 
General comment 
Previous research has highlighted concerns regarding the usage of APDs, which are primarily 
used to alleviate BPSD.6-7 Numerous studies have shown that APD therapy in individuals with 
dementia can have major negative effects, including death.15 Furthermore, it is unclear if APD 
use contributes considerably to the improvement of BPSD. An RCT of individuals with AD 
found that olanzapine and risperidone had a clear favorable impact in alleviating BPSD when 
compared to placebo and quetiapine.21 However, the advantages were only shown in those who 
were able to tolerate the drugs. We observed that APDs are associated with an increased risk 
of mortality in individuals with dementia. Several reasons have been proposed to explain why 
APD therapy increases mortality. Generally, atypical APDs, which occupy Dopamine D2 
receptors only transiently are thought to be associated with lower risk of EPS.40 However, when 
the dosage of APDs is taken into account, atypical antipsychotics are no safer than traditional 
antipsychotics in terms of development of Parkinsonism.41 Furthermore, cardio- and 
cerebrovascular events have been documented as a significant adverse effect of APD therapy.42 
High rates of ventricular arrhythmias and cardiac arrest have been linked to typical APDs,43 
whereas atypical APDs have been linked to high rates of venous thromboembolism. 44 Both 
typical and atypical APDs have been associated with QT prolongation.45 Studies suggest that 
whether the benefits of APDs outweigh the risks depends on the unique profile of the 
individual, which includes the specific BPSD characteristics and dementia severity.22 





6.4 GUN OWNERSHIP IN INDIVIDUALS WITH DEMENTIA (STUDY 4) 
 
In our cohort, 3.4% of individuals with dementia owned a firearm and one in five of them was 
considered unsuitable for its possession. However, a high percentage of individuals lacked 
information on firearm status. When compared to those who did not have a firearm, firearm 
owners were more likely to be younger, male, and live alone without the support of home care. 
Additionally, 23% of these individuals had a moderate severe or very severe dementia. 
Furthermore, even though the overall use of psychiatric medication was slightly lower in this 
group, 4% of persons with firearm used antipsychotic medication, 10% hypnotics and 24% 
antidepressants. Finally, living arrangement, dementia subtype, diagnostic unit, APD, 
hypnotics prescription, MMSE score, and gender were the most significant predictors of being 
reported to the police as unsuitable to own a firearm in SveDem. 
General comment 
Our findings suggest that individuals with dementia who possess a firearm are more 
independent and have better overall health, suggesting that they may still be able to safely use 
a firearm. However, several of these individuals had dementia that was either moderately 
severe or extremely severe. Furthermore, the general usage of psychiatric medicine indicates 
that psychiatric symptoms may be present in this group as well. It is difficult to assess a 
competence to handle a firearm in someone who has just been diagnosed with dementia. 
Removing the firearm automatically when a person is diagnosed with dementia may promote 
social isolation and threaten the individual's personhood. In Sweden, a combination of variables 
(type of dementia diagnosis, gender, severity of cognitive impairment, psychiatric medication, 
living arrangement) are considered when deciding whether or not to remove the firearm. 
However, our findings, as well as those of others, indicate that the subject of firearm status may 
be rarely raised in clinical settings.212–214 We suggest that the date of firearm retirement 
should be addressed in advance between individuals with dementia, their family members, and 
healthcare practitioners and individuals with dementia should take an active part in this 
decision. This manner, individuals with dementia's and their surrounding’s safety may be 





6.5 METHODOLOGICAL LIMITATIONS AND BIASES 
 
A valid study is the one with a low systematic error in estimations, typically referred to as 
biases.  Internal validity reflects the validity of the conclusions derived in relation to members 
of the source population. There are three main components of internal validity: confounding, 
selection bias, and information bias.215 
Confounding bias 
Confounding bias can be thought of as a conflation mix-up of effects.215 The influence of 
extraneous elements is mistaken for – or combined with – the real exposure effect, causing the 
apparent effect of the exposure of interest to be skewed. A confounding factor can cause 
significant distortion, leading to an overestimation or underestimation of an effect or affecting 
its direction. To be deemed a confounder, a variable must be linked to both the study's exposure 
and the outcome. In Studies 1 and 2, we did not have access to a number of possible 
confounding sources. Comorbidities, for example, are not recorded in the registries we utilized, 
thus they could not be accounted for in the studies. Furthermore, since there was no information 
regarding dementia severity at the time of enrollment in the BPSD registry, we utilized 
cognitive data (MMSE) at the time of dementia diagnosis, as well as the period between these 
two time points, as a proxy for severity. Additionally, MMSE score may be viewed as both a 
confounder and an intermediate factor in the BPSD study: on the one hand, MMSE score is 
one of the factors used to determine the diagnosis and hence has an impact on the diagnosis; 
on the other hand, MMSE score is used as a proxy for the pathogenic component that underpins 
the diagnosis-BPSD association.  
In Study 3, individuals who have been prescribed APDs differed considerably from those who 
have not been prescribed APD. They were more frail and more likely to reside in long-term 
care facilities. To address this issue, we modified our model to account for group differences. 
However, we cannot rule out the possibility that additional confounding variables that were not 
measured in the registries could have biased our findings and led to an overestimation of the 
association between APD and mortality. Other uncontrolled confounders, such as BPSD, may 
potentially be present in this study. BPSD, for which APD is prescribed, is linked to a higher 
death rate and may be a significant confounder in the relationship. However, we were unable 
to include them in the model. As a result, it is possible that the true association between APD 






Selection biases are errors that occur as a result of subject selection methods and other factors 
that impact participation in a study.215 The relationship between exposure and disease is 
different for those who participate and all those who should have been theoretically eligible for 
investigation, including those who do not participate. Therefore, the associations identified in 
research represent a combination of variables that determine participation and forces that 
determine disease incidence since estimates of effects are conditioned on participation. 
Selection bias usually happens at the first stages of a study, when patients are recruited, or later 
in the research, when patients are lost during follow-up. As a result of the selection bias effect, 
the estimate obtained from the research participants differs from the estimate obtainable from 
the target population. 
In 2020, the SveDem coverage of incident dementia cases was expected to be 43%,166 while 
the BPSD registry coverage of patients with dementia residing in nursing homes was estimated 
to be about 40%.173 It is unclear how the individuals who participate in SveDem and BPSD 
vary from those who have not. The individuals in quality registers were shown to be healthier, 
receive better quality of care and have lower risk of death, skewing the generalizability towards 
this pattern.216 In Study 1-2, more troublesome BPSD like  hyperactivity could be one of the 
reasons for moving a person with dementia to a long-term care facility. Therefore, in our 
studies, their frequency could be overestimated and the results cannot be generalized to 
individuals with dementia living in a community. The majority of gun owners in Study 4 live 
in northern Sweden, which is underrepresented in SveDem. As a result, the study's total number 
of individuals owning a firearm may be underestimated. The non-responders may differ in 
several characteristics in comparison to persons included in the study and therefore affect the 
estimation. Furthermore, individuals in these areas may be diagnosed more often in primary 
clinics rather than memory clinics, which might lead to additional biases in selection. 
Individuals in primary care are older, have slightly fewer neuropsychological examinations, 












Information bias refers to measurement inaccuracies in exposure, confounders or outcomes.215 
In the case of discrete variables, measurement error is commonly referred to as classification 
error or misclassification. 
Dementia diagnosis in SveDem is based on clinical criteria. Clinical diagnosis has a lower 
overall sensitivity than the neuropathological examination. Nonetheless, diagnoses made at 
baseline in SveDem are seldom modified.217 In Study 3, we used data from the SPDR about 
the filled prescriptions. The identification of people who fill prescriptions is not always the 
same as the identification of those who actually take the medicine. This bias might cause the 
effect to be overestimated. Another sort of misclassification bias known as "recall bias" may 
have had an impact on the results in Study 1, 2 and 4. For example, caregivers may find it easier 
to recall more stressful symptoms that lead to increased burden, resulting in an overestimation 
of their frequency. Given the self-reporting nature of the firearm ownership status in Study 4, 
it is likely that some people opted to conceal this information or were unable to recollect it due 





7.1 GENERAL CONCLUSIONS 
Individuals with dementia who live in long-term care facilities frequently develop BPSD. 
Despite the fact that our sample included variety of dementia diagnoses, they all had a high 
frequency of irritability, aberrant motor behavior and agitation/aggression. We also observed a 
high frequency of unmet needs, the most prevalent of which were pain, sleeping problems, 
impaired hearing and vision. In each dementia type, there was a positive association between 
the number of unmet needs and BPSD. Individuals with dementia are prescribed both typical 
and atypical APDs. Their usage, however, was associated with an increased risk of mortality. 
In our study, 3.4% of individuals with owned a firearm. Gun owners were younger men who 
were still living more independent lives. The decision to remove the firearm was not made 
solely on the basis of a dementia diagnosis, but a combination of factors was considered.  
 
7.2 SPECIFIC CONCLUSIONS 
 
1. BPSD is common among individuals with dementia residing in long-term care facilities 
with 75% of all individuals exhibiting at least one clinically significant BPSD. 
2. Amongst all symptoms, aberrant motor behaviour, agitation and irritability were the most 
frequent, occurring commonly in all dementias. 
3. Despite the fact that the individuals in our sample had various dementia diagnoses, we 
found similarities in the type of their symptoms. 
4. Unmet needs are commonly present in individuals with dementia. 
5. In the entire cohort, pain was the most prevalent unmet need, followed by sleeping 
disturbances and impaired hearing and impaired vision.  
6. BPSD increases in the presence of physical or psychological unmet needs, regardless of the 
type of dementia. 
7. Use of APDs at the time of dementia diagnosis was associated with increased mortality risk 
in individuals with AD, Mixed, UNS, and VaD. 
8. Higher risk for mortality was found with typical APDs in individuals with Mixed and VaD. 
9. Atypical APDs were related with higher risk for mortality in individuals with AD, Mixed, 
UNS, and VaD. 
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10. Of all individuals included in the study, 3.4% owned a firearm, of whom 22.2% were 
reported as unsuitable to own it. 
11. Almost one-fifth of individuals included in the study lacked information on their firearm 
status. 
12. When deciding whether or not to remove the firearm, physicians take a number of criteria 
into consideration, including the type of dementia diagnosis, gender, level of cognitive 





8 POINTS OF PERSPECTIVE 
 
…that is, who authored the painting on the cover of this Thesis? 
 
Diagnostic systems that classify symptoms improve the understanding of mental illness and 
help its treatment.218 Moreover, formal diagnosis provides an explanation for the symptoms 
and thereby may decrease the anxiety caused by unknown cognitive problems - both among 
patients and their caregivers.219 A formal diagnosis also may increase the sense of control over 
the course of the disease and can promote finding ways of adjusting to the changes 
experienced.2 However, diagnosis can be also seen as a label that triggers cognitive processes 
of stereotypization.218  Stereotypes are knowledge structures that are learned by most members 
of a cued social group.220 Individuals with a label (diagnosis) are perceived within the frame of 
a stereotype, as homogeneous and that their traits are stable (not subject to change or influence 
of the environment). This prevents recognition of the idiosyncratic characteristics of each 
patient and impedes a comprehensive understanding of their behavior. For this reason, 
receiving the diagnosis carries the risk of stigmatization and marginalization of people with 
mental illness. Perhaps the most striking example of stigmatization associated with diagnosis 
is a pathologization of the behavior of individuals with dementia. Dementia is commonly 
interpreted as a partial or complete loss of self, until “there is nothing left”.80 Following this, 
the behavior of the person who has “lost self” is treated as lacking internal locus of control or 
intentionality, and therefore labelled as disorganized or abnormal. 
Although not explicitly stated, this interpretation of dementia is embedded in the prevalent in 
dementia research a Cartesian perception of the relationship between mind and body. Descartes 
effectively separated mind and body in the seventeenth century, with the mind taking 
precedence over the body. While the mind is considered to be the most important aspect of 
selfhood, the Cartesian dualism implies that the body is fundamentally passive. Therefore, the 
widely held belief that cognitive decline entails a loss of selfhood has philosophical roots. In 
this view, the existential degradation of selfhood associated with Alzheimer’s disease is, to a 
considerable measure, the outcome of a philosophical heritage, rather than just neuropathology.  
Thus, the idea of selfhood in dementia is strictly bound to Cartesian perception of the dualisms 
of mind and body. In the case of persons with dementia, it is a body that takes control over a 
disrupted mind. In western culture, self is equated with cognitive mind and this is reflected in 
the scientific discourse around dementia, currently dominated by the biomedical model. The 
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biomedical model focuses exclusively on pathological brain changes occurring in dementia, 
and overlooks the contribution of external factors to the emergence of BPSD. Moreover, 
although there were attempts to create comprehensive models of BPSD,34 discussions about 
personality changes are not embedded in any psychological theories of personality or 
emotions.  
Kales and colleagues' model resembles the personality system suggested in 1995 by Mischel 
and Shoda.221 According to their cognitive-affective system of personality, the behavior of a 
person can be predicted from a comprehensive understanding of the person, the situation, and 
the interaction between person and situation.221 In contrast to the conceptions of personality as 
dispositions, behavior emerges from the individual’s perception of themselves in a particular 
situation. People can be characterized by the stable patterns of behaving differently in various 
situations. From this perspective, it is important to see the context in which the behavior occurs. 
Aggressive behavior can be a reaction to bathing and result from misunderstanding the situation 
as threatening. It is possible that the behavior would not appear in a different context. The 
perception of the situation can be influenced both by the external factors (e.g. behavior of 
caregiver, relation to caregiver) and factors associated with the patient themselves (e.g. type 
and severity of neurodegeneration).  
The underlying philosophy employed by researchers of causes of behavior has important 
implications in the perception of the behavior of the individual, and consequently translates 
into research questions and the framing of hypotheses. This has further consequences in 
treatment and decisions about implementing pharmacological intervention. The exclusion of a 
psychological perspective in explaining BPSD may come from the notion that 
neurodegeneration overrides individual differences. Although this can be true in some cases, 
different studies conclude that the role of environment, caregivers and premorbid personality 
seem to contradict this conception.6 
Therefore, it seems that there is a need for a new framework to approach behavior of persons 
with dementia. In the embodied selfhood framework, the quest for selfhood of the person 
affected by dementia is given priority.80 To this end, researchers look for “selfhood beyond 
cognition”. This emerging perspective integrates Merleau-Ponty's understanding of non-
representational intentionality and the primordial body with Bourdieu's idea of habitus,9 which 
connects bodily dispositions to social world structures.222–224 The most significant aspect of 
Merleau-Ponty's perspective is the idea that there is a fundamental level of existence that does 
not include a cognitive form of awareness.9 As a result, the pre-reflective body is directed 
toward the world without the need for a reflective comprehension of how it is directed. In her 
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ethnographic studies, Kontos (2004) gives the following example of such an approach 
describing one of the participants of her study passing the doorway: “…just as we all go 
through a doorway without checking the width of the doorway against that of our body. This 
was evidenced by the recognizable fluidity to their gait: it had not become, as a result of the 
walker, a sequence of partial movements strung laboriously together. Clearly, they were not 
pausing to evaluate the respective measurements of their walker and the space to be 
navigated.”225  From this perspective, selfhood is found in the existential expressiveness of the 
body that arises from our ability to act, the know-how of a person whose primary relationship 
to the environment is one of pre-reflection, action, and practical engagement.80,222 Bourdieu, 
on the other hand, claims that the conditioning connected with membership in a certain social 
class, through one's relationship to one's own body, tends to inculcate in persons’ tendencies 
and generative schemes for being and seeing, which he refers to as habitus.223,224 To put it 
another way, habitus is a way of being that is embodied in humans and turned into motor 
schemes and bodily automatisms, which manifest as postures, gestures, and motions. 
Altogether, according to the embodied perspective on selfhood, our selfhood is not limited by 
the rigid frame dictated by Cartesian dimensionality, but can be found in the way we move, in 
our gestures and the mimics of our faces. Similarly, persons whose minds were affected by 
neurodegeneration do not cease to be persons but maintain what constituted the very essence 
of them in the way they engage with their surroundings. Also, their behavior bears a meaning 
in a given context and can be a valuable source of information for their relatives and caregivers. 
cIf dementia truly equates the destruction of selfhood and disorganized, uninhabited behavior, 
then who authored the painting on the cover of this Thesis? Marian Siwek, born in 1936, was 
a Polish artist-outsider who always contested the ruling political system. In his final years, the 
artist once again excluded himself from public life - this time the cause was Alzheimer's 
disease. Despite the progression of the disease, Marian Siwek did not stop creating. The 
soundness and intensity of expression of Marian Siwek’s later work, as well as those of 
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mojego taty, Pawła, który zawsze ma świetne pomysły na grant; moich braci – Tomka i Kuby 
– bez których generalnie byłoby słabo.    
Zawsze mogłabym liczyć na wsparcie moich najlepszych w świecie przyjaciół, a dokładniej 
Wyraka, który zainwestował majątek w moja edukację i ciągle czeka na zysk; Kasi, która 
inwestuje majątek w Wyraka i ciągle czeka na zysk; Manushki, która może kiedyś znajdzie 
odpowiednie miejsce na bunkier, bo jak przyjdzie wojna, to dalej trzeba będzie płacić ratę za 
mieszkanie ale trudno powiedzieć, bo w sumie nie ma precedensu; Mateusza, rozpoznawalnej 
w Krakowie gwiazdy punk rocka, który gra na festiwalach, i nawet w Warszawie; naczelnego 
Vege Runners Pająka, który nieustannie i bez zmęczenia rozwija big biznes, uzupełniając 
asortyment sklepu Vege Runners coraz to nowymi wzorami kapuścianych koszulek; hakera i 
znanego łamacza internetowych serc Radka C., który, od wspólnego mieszkania, już zawsze 
sprząta, bo zobaczył, jak to jest, kiedy mieszka się z kimś, kto nie sprząta; Asi M. której 
wrażliwość, zawsze była dla mnie inspiracja, Asi B., która jest moja przyjaciółka pomimo tego, 
ze zna mnie już 26 lat!!!; Justynie K, przyjaciółce oraz sezonowej współpracowniczce z 
młodosci, która zawsze potrafi rozbawić otoczenie ciekawymi historiami, np. tymi o 
narożniczku; Paulinie Sz, z którą praca z finometrem przekształciła się w przyjaźń…w końcu 




Chciałabym także podziękować Michałowi K. i Joasi P., moim opiekunom pracy 
magisterskiej z Uniwersytetu Jagiellońskiego w Krakowie, którzy wprowadzili mnie w świat 
badań i nauki. Praca z Wami zawsze była ekscytująca, trochę dziwna, a przede wszystkim 
super fajna i fascynująca!  
Finally, I'd want to express my gratitude for all of the funds that enabled me to do this 
research: Gun och Bertil Stohnes Stiftelse, CIMED grant, Alzheimerfonden, Swedish Brain 
Foundation, and Margaretha af Ugglas’ foundation and Swedish Research Council and by 
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